Landogrozumab

Landogrozumab is a monoclonal antibody designed for the treatment of osteoporosis. It works by inhibiting a protein called sclerostin, which is a negative regulator of bone formation. By blocking the action of sclerostin, landogrozumab promotes bone formation and decreases bone resorption, thereby increasing bone mass and strength.

Mechanism of Action

Landogrozumab is a humanized monoclonal antibody that binds to and inhibits the activity of sclerostin. Sclerostin is a protein produced by osteocytes (mature bone cells) that inhibits bone formation. It does this by binding to low-density lipoprotein receptor-related protein 5 (LRP5) and LRP6 on osteoblasts (bone-forming cells), preventing them from receiving signals to produce more bone. By blocking the action of sclerostin, landogrozumab allows these signals to be received, leading to increased bone formation.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of landogrozumab in the treatment of osteoporosis. These trials have shown that landogrozumab can significantly increase bone mineral density and reduce the risk of fractures in postmenopausal women with osteoporosis.

Side Effects

Like all medications, landogrozumab can cause side effects. The most common side effects reported in clinical trials include back pain, joint pain, and headaches. Rare but serious side effects can also occur, including hypocalcemia (low calcium levels in the blood) and osteonecrosis of the jaw (a condition in which the jaw bone starts to die).

See Also

• Monoclonal antibodies
• Osteoporosis
• Sclerostin
• Clinical trials

Landogrozumab Resources
Latest articles Most recent articles Ongoing trials	Wikipedia